Zenotech Laboratories Q1FY26: Loss narrows to ₹0.46 cr

Q1FY26 result: loss narrows as revenue improves

Zenotech Laboratories Ltd reported a standalone net loss of ₹0.46 crore for the quarter ended June 30, 2026 (Q1FY26), compared with a loss of ₹0.99 crore in the year-ago period, as per the company’s quarterly numbers provided. Revenue grew year-on-year, but operating costs rose faster, keeping the company in the red. The Hyderabad-based pharmaceutical company’s revenue from operations increased on the back of stable rental-led operating income linked to a biotech facility and equipment leased to Sun Pharmaceutical Industries Limited.

The quarter is notable for two reasons. First, the topline expanded at a steady pace despite a muted operating profile. Second, expenses rose sharply, driven by employee-related costs and other expenses, which offset the revenue improvement.

Revenue from operations rises 11% YoY

For Q1FY26, revenue from operations came in at ₹9.60 crore, up 11.1% from ₹8.64 crore in Q1FY25. Total income increased 8.0% year-on-year to ₹11.05 crore from ₹10.23 crore.

The details show that other operating income was broadly steady at ₹1.02 crore versus ₹1.00 crore a year ago. Other income, however, declined to ₹0.44 crore from ₹0.59 crore.

The company attributed its consistent other operating income primarily to rentals for its biotech facility and equipment leased to Sun Pharmaceutical Industries Limited. This rental stream remained a meaningful part of the overall income mix during the quarter.

Cost pressures: expenses jump 30% year-on-year

Total expenses rose 30.1% year-on-year to ₹11.65 crore in Q1FY26 from ₹8.95 crore in Q1FY25. The increase was led by higher employee benefit expenses and higher other expenses.

Employee benefit expenses were reported at ₹4.92 crore versus ₹3.54 crore in the corresponding quarter last year. Other expenses increased to ₹4.83 crore from ₹3.65 crore. Depreciation and amortisation also moved up to ₹1.90 crore from ₹1.77 crore.

With expenses rising substantially faster than total income, the quarter ended with negative profitability despite the higher revenue base.

Profitability snapshot: PBT turns negative

The summary data indicates a pre-tax loss of ₹0.60 crore in Q1FY26, versus a pre-tax profit of ₹1.28 crore in Q1FY25. Tax expense was lower at ₹(0.15) crore compared with ₹0.29 crore in the prior-year quarter, contributing to the net loss being contained.

Separately, the provided market note also frames the comparison as a net loss of ₹0.46 crore in June 2026 versus a net profit of ₹0.99 crore in June 2025. Readers tracking the company should rely on the signed financial statements and the final approved numbers for the definitive year-on-year comparison.

Key financials (standalone) at a glance

All figures below are normalised to ₹ crore (1 crore = 100 lakh), based on the data provided.

*The provided data includes both a table and a market note that reference the prior-year quarter outcome. The market note states Q1FY25 net profit of about ₹0.99 crore.

Auditor review: unmodified conclusion

The statutory auditors, G S K A & Co., issued an unmodified review on the quarterly results referenced in the provided material. An unmodified review indicates that the auditors did not flag material modifications to the outcome of their review, based on the limited review procedures applicable for quarterly financials.

The same auditor firm is also referenced in the broader corporate governance updates provided alongside the results context.

AGM date: shareholder meeting scheduled in September

Zenotech’s 37th Annual General Meeting (AGM) is scheduled for September 25, 2026, as stated in the provided information. AGM announcements typically include statutory business, governance approvals, and shareholder resolutions. The scheduled date is a key corporate calendar item for investors who track approvals around auditor appointments and other governance matters.

What the numbers suggest for investors

The quarter highlights a familiar pattern for smaller pharma and manufacturing-linked businesses with a meaningful share of rental or other operating income. Revenue growth is visible, and other operating income remains stable, but fixed and semi-fixed costs can swing the bottom line quickly.

The sharp year-on-year increase in employee benefit expenses and other expenses was the central driver behind the loss for Q1FY26. At the same time, the fall in other income reduced an additional cushion that could have supported profitability.

Market datapoints referenced alongside results

A separate results snippet in the provided content reiterates the topline growth and the net loss outcome in crore terms: sales of ₹9.60 crore in the June 2026 quarter versus ₹8.64 crore a year earlier, and net loss of ₹0.46 crore versus net profit of ₹0.99 crore.

While these snapshots are consistent with the revenue from operations figures, investors typically cross-check them with the company’s filed financials to ensure consistent classification of income and profit metrics.

Conclusion

Zenotech Laboratories’ Q1FY26 standalone results showed higher revenue and steady rental-linked operating income, but a 30% jump in expenses kept the company loss-making at ₹0.46 crore. The unmodified auditor review and the scheduled 37th AGM on September 25, 2026 are the next formal checkpoints in the company’s disclosure calendar.